Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Regeneron Pharmaceutical (REGN)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Latest Headlines for [[ item.sessionDateDisplayLong ]]
Watch for Regeneron Pharm to Potentially Rebound After Falling 1.72% Yesterday

Regeneron Pharm (NASDAQ:REGN) traded in a range yesterday that spanned from a low of $398.20 to a high of $403.02. Yesterday, the shares fell 1.7%, which took the trading range below the 3-day low of...

REGN : 391.80 (-2.68%)
Atopic Dermatitis Market Highest Growth in Healthcare with Size, Share, Price Trend, Foreseen by 2023

VRX.TO : 30.80 (-3.33%)
ANAC : 99.06 (-0.14%)
AGN : 149.30 (-2.76%)
ALPMF : 15.6300 (+1.26%)
NVS : 93.42 (-0.26%)
REGN : 391.80 (-2.68%)
PFE : 41.85 (-1.18%)
BMY : 48.16 (-1.55%)
Should You Invest in the Invesco Dynamic Biotechnology & Genome ETF (PBE)?

Sector ETF report for PBE

PBE : 53.63 (-3.85%)
IBB : 108.17 (-3.39%)
ALNY : 84.52 (-6.85%)
QGEN : 39.42 (-2.26%)
REGN : 391.80 (-2.68%)
XBI : 87.86 (-4.42%)
Regeneron, Sanofi Get EC Nod for Label Expansion of Praluent

Regeneron (REGN) and partner Sanofi receives approval in Europe for the label expansion of Praluent to reduce cardiovascular (CV) risk in adults with established atherosclerotic CV disease.

BAYRY : 16.6350 (-3.90%)
REGN : 391.80 (-2.68%)
AMGN : 186.70 (-2.70%)
SNY : 44.26 (-2.58%)
Inovio's Early/Mid-Stage Vaccine Pipeline Exhibits Growth

Inovio's (INO) most advanced candidate, VGX-3100 vaccine, is advancing well. Heavy reliance on partners for funds to develop its pipeline candidates is a persistent concern.

AZN : 42.59 (-0.84%)
INO : 3.62 (-2.69%)
RHHBY : 33.7600 (-1.06%)
REGN : 391.80 (-2.68%)
Praluent® (alirocumab) now approved in European Union to reduce the risk of cardiovascular events in patients with established cardiovascular disease

Approval is based on ODYSSEY OUTCOMES trial of 18,924 patients who recently suffered an acute coronary syndrome such as a heart attack

REGN : 391.80 (-2.68%)
10 Stocks Powering S&P 500 ETF in the 10-Year Bull Run

Though most of the stocks in the S&P 500 ETF have delivered astounding returns during the decade, a few were the real stars, skyrocketing more than 2000%.

NFLX : 361.01 (-4.46%)
ULTA : 330.52 (-1.38%)
ABMD : 323.21 (-4.21%)
INCY : 85.34 (-2.00%)
WCG : 241.84 (-3.27%)
REGN : 391.80 (-2.68%)
ALGN : 269.62 (-3.96%)
URI : 110.96 (-6.80%)
SPY : 279.25 (-1.92%)
BKNG : 1,721.59 (-2.97%)
AMZN : 1,764.77 (-3.00%)
Biotech Stock Roundup: REGN Gets FDA Nod for Dupixent & Other Pipeline News

Key highlights of the past week are regulatory and pipeline developments.

CELG : 88.15 (-1.65%)
VRTX : 181.53 (-0.56%)
ZFGN : 2.84 (-5.02%)
AMAG : 12.16 (-4.33%)
REGN : 391.80 (-2.68%)
SNY : 44.26 (-2.58%)
Inovio (INO) Misses on Q4 Earnings & Revenues, Shares Down

Inovio Pharmaceuticals (INO) reports results for fourth quarter of 2018 wherein loss and revenues both miss estimates.

AZN : 42.59 (-0.84%)
INO : 3.62 (-2.69%)
RHHBY : 33.7600 (-1.06%)
REGN : 391.80 (-2.68%)
Regeneron and Sanofi to Present New Praluent® (alirocumab) Data at ACC.19

Sub-analyses from ODYSSEY OUTCOMES trial, including featured clinical research, provide new Praluent insights

REGN : 391.80 (-2.68%)
10 Stocks Powering S&P 500 ETF in the 10-Year Bull Run

Though most of the stocks in the S&P 500 ETF have delivered astounding returns during the decade, a few were the real stars, skyrocketing more than 2000%.

NFLX : 361.01 (-4.46%)
ULTA : 330.52 (-1.38%)
ABMD : 323.21 (-4.21%)
INCY : 85.34 (-2.00%)
WCG : 241.84 (-3.27%)
REGN : 391.80 (-2.68%)
ALGN : 269.62 (-3.96%)
URI : 110.96 (-6.80%)
SPY : 279.25 (-1.92%)
BKNG : 1,721.59 (-2.97%)
AMZN : 1,764.77 (-3.00%)
Teen Scientists Win $1.8 Million at Regeneron Science Talent Search 2019 with Innovative Ideas on Exoplanets, HIV and a Classic Math Problem

Regeneron Pharmaceuticals, Inc. and Society for Science & the Public announced that Ana Humphrey, 18, of Alexandria, Virginia, won the top award in the Regeneron Science Talent Search, the nation's oldest...

REGN : 391.80 (-2.68%)
Teen Scientists Win $1.8 Million at Regeneron Science Talent Search 2019 with Innovative Ideas on Exoplanets, HIV and a Classic Math Problem

Top award of $250,000 goes to Ana Humphrey of Virginia in nation's oldest and most prestigious STEM competition for high school seniors

REGN : 391.80 (-2.68%)
Regeneron/Sanofi's Dupixent Gets FDA Nod for Label Expansion

The FDA approves a label expansion of Regeneron's (REGN) asthma drug, Dupixent for moderate-to-severe atopic dermatitis in adolescents.

BAYRY : 16.6350 (-3.90%)
CELG : 88.15 (-1.65%)
REGN : 391.80 (-2.68%)
SNY : 44.26 (-2.58%)
FDA Approves Dupixent® (dupilumab) for Moderate-to-severe Atopic Dermatitis in Adolescents

Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Sanofi today announced that the U.S. Food and Drug Administration (FDA) has approved Dupixent® (dupilumab) for adolescent patients 12 to 17 years of...

REGN : 391.80 (-2.68%)
Sanofi's Dupixent Gets FDA Priority Status for Nasal Polyps

Sanofi (SNY) and partner Regeneron's (REGN) Dupixent gets FDA's priority review status for inadequately controlled severe chronic rhinosinusitis with nasal polyps.

BAYRY : 16.6350 (-3.90%)
AZN : 42.59 (-0.84%)
REGN : 391.80 (-2.68%)
SNY : 44.26 (-2.58%)
New Genetic Data from Regeneron and GSK on 50,000 UK Biobank Participants Made Available to Global Health Research Community

All sequenced data linked to detailed health-related records, creating first widely available 'Big Data' resource of its kind

REGN : 391.80 (-2.68%)
Regeneron Announces Upcoming Investor Conference Call

Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) will webcast management participation as follows:

JPM : 99.76 (-3.02%)
REGN : 391.80 (-2.68%)
Regeneron (REGN) Up 0.8% Since Last Earnings Report: Can It Continue?

Regeneron (REGN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

REGN : 391.80 (-2.68%)
FDA to Undertake Priority Review of Dupixent® (dupilumab) for Adults with Inadequately Controlled Severe Chronic Rhinosinusitis with Nasal Polyps

Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Sanofi today announced that the U.S. Food and Drug Administration (FDA) has accepted for Priority Review the supplemental Biologics License Application...

REGN : 391.80 (-2.68%)

Van Meerten Stock Picks

Trilogy Metals - Pick of the Day
My Stock Pick of the Day belongs metal mining company Trilogy Metals(TMQ).
TMQ -0.16
Jim Van Meerten uses Barchart's tools to offer daily stock picks and recommendations. His portfolios have been honored by Marketocracy and Morningstar.

InsideFutures Commentary

InsideFutures is a twice weekly newsletter that features a selection of the latest and best commodities commentary appearing on Barchart.com. Delivered every Wednesday and Friday morning to your inbox.

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar